文献速递临床试验与 GCP真实世界研究与卫生经济

普瑞巴林治疗难治性广泛性焦虑障碍的随机对照试验方案

PrEgabalin for Treatment Resistant generalised Anxiety disorder (PETRA): study protocol for a double-blind randomised controlled trial set in the UK.
PubMed 文献 · Trials · 2026-09-03

PETRA是一项在英国基层医疗开展的多中心、个体随机、双盲、安慰剂对照优效性试验,计划纳入498例对至少一种抗抑郁药疗效不佳或部分应答的广泛性焦虑障碍成人患者,评估在抗抑郁药基础上加用普瑞巴林26周的临床与成本效果,主要终点为12周时GAD-7焦虑评分。

要点

  • 针对抗抑郁药未充分应答的GAD成人,加用普瑞巴林26周并逐渐减量。
  • 主要终点为12周GAD-7连续评分,随访至约30周评估撤药期症状。
  • 样本量498例,从约150家全科诊所招募,1:1最小化随机分组。

核心结论

  • 该方案拟评估普瑞巴林加用于抗抑郁药治疗未充分应答的GAD患者的临床与成本效果,结果尚未报告。

研究设计与样本

  • 多中心、个体随机、双盲、安慰剂对照优效性试验,在英国基层医疗开展。
  • 从约150家全科诊所招募,按1:1最小化随机分配至普瑞巴林或匹配安慰剂,疗程26周后约4周逐渐减量。
  • 计划样本量498例;随访评估在3、6、12、26和约30周进行。

关键数值与推荐

  • 纳入18-74岁成人,正在服用抗抑郁药至少8周,且当前抗抑郁药之前已接受至少一种其他抗抑郁药治疗。
  • 需符合ICD-11广泛性焦虑障碍诊断标准,且修订版临床访谈量表(CIS-R)总分≥12。
  • 主要结局为12周时GAD-7焦虑症状连续评分。
  • 次要结局包括其他时点GAD-7、抑郁与惊恐症状、自杀意念、自评总体改善、服药依从性、严重不良事件、不良反应、酒精消耗与苯二氮䓬类药物使用、生活质量及资源与成本使用。

临床怎么用

  • 若取得阳性结果,可为基层医生对未充分应答的GAD患者在抗抑郁药基础上加用普瑞巴林提供处方依据。
  • 约30周评估将提供普瑞巴林撤药期症状信息,有助于指导减量策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Generalised anxiety disorder (GAD) is common and increasingly recognised in primary care. Although antidepressants and psychological therapies are first-line treatments, many patients have residual anxiety and limited access to therapy. Evidence for effective next-step pharmacological options for treatment resistant anxiety remains limited. This paper describes the protocol for the PETRA trial, which will evaluate the clinical and cost-effectiveness of adding pregabalin to antidepressant treatment, compared with placebo, for people with GAD who have not responded or partially responded to antidepressant treatment. METHODS: PETRA is a multicentre, individually randomised, double-blind, placebo-controlled superiority trial conducted in UK primary care. Participants are recruited by the study team from approximately 150 General Practices and randomised in a 1:1 ratio, using minimisation, to either pregabalin or a matching placebo for 26 weeks (followed by a tapering period where their dosage is reduced over approximately 4 weeks). Sample size is 498. Eligible participants are adults aged 18-74 years, who have been taking antidepressant medication for at least 8 weeks, received treatment with at least one other antidepressant before their current antidepressant and meet ICD-11 criteria for GAD and score ≥ 12 on the revised clinical interview schedule (CIS-R) total score. Follow-up assessments are at 3, 6, 12, 26 and ~ 30 weeks. Our primary outcome measure will be anxiety symptoms measured with GAD-7 at 12 weeks (continuous score). Secondary outcomes are anxiety (GAD-7) at other time points, depressive and panic symptoms, suicidal thoughts, self-rated global improvement, adherence to study medication, serious adverse events, adverse effects, alcohol consumption and benzodiazepine use, quality of life and resources and costs used. The ~ 30-week assessment will investigate symptoms during the withdrawal from pregabalin. Exploratory analyses will include cognitive tasks. A cost-effectiveness analysis and a nested qualitative study will evaluate the implementation and intervention acceptability. DISCUSSION: The trial findings will inform primary care prescribing practice by providing an accurate and generalisable estimate of the clinical and cost-effectiveness of prescribing pregabalin to individuals with generalised anxiety who have not responded or only partially responded to antidepressant treatment. TRIAL REGISTRATION: Controlled Trials ISRCTN Registry, ISRCTN 16993990, registered on 19/09/2023. First participant enrolled in January 2024.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Duffy L, Chew-Graham CA, Ching BCF, et al. PrEgabalin for Treatment Resistant generalised Anxiety disorder (PETRA): study protocol for a double-blind randomised controlled trial set in the UK. Trials. 2026. PMID: 42717383. doi:10.1186/s13063-026-09949-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。